Try our Advanced Search for more refined results
Life Sciences - July, 2019
348 articles
- Ex-J&J Doctor Testifies She Told Bosses About Mesh Issues
- $17B Or Zilch? Okla., J&J Make Final Pitches After Opioid Trial
- Why Ariz. Is Taking Aim At The Sacklers At The High Court
- True Health Gets Nod For $7.8M DIP After Deadline Shift
- Arbitrator Told To Clarify Trading Firm's $3.6M Award
- J&J Tried To Invade Atty Privilege In Talc Case, Judge Told
- PhRMA's New Attack On Calif. Drug Pricing Law Gets Traction
- Drug Distributor's Ex-CEO Faces May Trial Over Opioid Sales
- Offit Kurman Nabs 4 IP Specialists From Caesar Rivise
- Amarin Asks Justices To Get ITC To Look Into False Ad Claims
- European Venture Outfit Raises $233M For Life Science Fund
- Rosen Law To Lead Indivior Stock Suit Over Opioid Indictment
- Fed. Circ. Upholds PTAB Ax Of Avastin Patent
- Celgene To Pay $62M To End Antitrust Suit Over Cancer Drugs
- Gene Therapy, Drilling Contractor Raise $101.5M In Debuts
- Debunking 3 Myths About Contract Attorneys
- Arizona Files Supreme Court Lawsuit Over Opioid Crisis
- HHS Opens Door To Drug Imports Amid Shaky Pricing Efforts
- J&J 'Would Never Sell' Unsafe Talc, Rep Says In Ky. Trial
- J&J Says FDA, Scientists Found No Asbestos In Baby Powder
- Ex-USPTO Directors, Judges Back Patent Eligibility Overhaul
- Texas Opioid MDL Gets 2020 Trial Dates
- Fed. Circ. Backs Retroactive IPRs, But The Fight Isn't Over
- Pharma Cos. Settle Patent Challenge Over Opioid Treatment
- Diagnostic Firm Says Medicare Holdback Pushed It Into Ch. 11
- Merck, Glenmark Rip Zetia Buyers' Par Deal As 'Tactical Move'
- EEOC Roundup: 7 Things You May Have Missed
- Cancer Biotech Oasmia Hid Deals From Investors, Suit Says
- Mylan Nears $30M Deal In SEC EpiPen Probe; CEO To Retire
- Fed. Circ. Won't Rethink Ruling Invalidating 2 Vimovo Patents
- Ex-Trump Adviser Returns To Baker Donelson Via Alliance
- Vitamin Maker Must Stop Using 'Sugar Bear Hair' Mark
- NJ Appeals Court Revives Homeopathic Flu Remedy Suit
- Wilson Sonsini Nabs Life Sciences, IP Whiz From Jones Day
- The Unique Challenges Of Owning International Cannabis IP
- Patient Drug Guides Vs. The Learned Intermediary Doctrine
- Fate Of CVS-Aetna Deal In The Hands Of Judge
- J&J Lied In Mesh Marketing, Surgeon Tells Calif. Judge
- Hospitals, Insurers Lash Trump's Price-Transparency Demand
- Women Can Drop, Refile Warning Label Suit Over J&J Talc
- Generic Lamictal Buyers Defend Class Cert. At 3rd Circ.
- Pot Dispensary Chain Fires Back Over Ill. License Sale Suit
- Puma Biotech Says Liability Still Unsettled In Stock-Drop Row
- Cancer Patients Breathed In 'Clouds' Of J&J Talc, Jury Told
- CVS To Pay $15M For Unwanted Flu Shot Calls
- Contradiction Ends Amgen's Neulasta IP Suit, Fed. Circ. Says
- 7th Circ. Revives LabCorp Unit Tech's Retaliation Suit
- NY Pharmacist Cops To Role In 'Brazen' $5M Opioid Ring
- Rite Aid Investors Seek Cert. In Failed Walgreens Merger Suit
- Bayer Cornering Market On Pet Tick Meds, Antitrust Suit Says
- Lawmakers Push Bill To Simplify Biosimilar Patent Fights
- Leaked Email In Price-Fixing Case Is Privileged, Heritage Says
- Teva, Endo Curb Pay-For-Delay Pacts In $70M Deal With Calif.
- 'No Miscarriage Of Justice' In Insys Execs' Trial, Feds Say
- 4 Firms Guide Israel-Based Inmode's $75M IPO Pricing
- 3 Firms Lead $2.8B Merger Of Cancer Treatment Developers
- 4 Firms Lead Pfizer Unit's Merger With Mylan
- Law360 Reveals The Global 20 Firms Of 2019
- St. Jude Hit Humana With Faulty Pacemaker Costs, Suit Says
- Meet The Top Attys In Gilead's 'No Generics' Antitrust Rumble
- J&J Unit Urges Philly Judge To Ax Risperdal Damages Trial
- Boston Scientific On Hook For $275M Merger, Chancery Told
- Opioid Seller Seeks To Lead Antitrust Class Despite Charges
- SEC Cuts Deal With Biotech Co. Pump-And-Dump Witness
- AARP Backs Up FTC At 3rd Circ. In AbbVie Antitrust Suit
- Eye Product Co. Says Feds' Attys Breached No-Contact Rule
- Stimwave Appeals Injunction In Spinal Cord Device IP Suit
- Compliance Imperatives For Defensible Data Disposal
- Lawmakers Still Looking For More NAFTA 2.0 Improvements
- AGs Fire Back After Pharma Bid To End Price-Fixing Claims
- First SF Project Under New Plan Gains Approval
- A Litigator's Reflections From The Arbitrator's Chair
- Health Hires: Epstein Becker, Morgan Lewis, Polsinelli
- Monsanto's $2B Roundup Cancer Loss Slashed To $87M
- Colgate, J&J Talc Contained No Asbestos, Geologist Tells Jury
- Florida Wants Redo On Ruling That Gutted Medical Pot Regs
- J&J Takes Aim At Testing Records At NJ Asbestos Talc Trial
- Quick Alice Wins Dwindling In Wake Of Berkheimer Ruling
- Prosthetic Maker Urges FTC To Reverse ALJ Acquisition Block
- PTAB Will Review Hep B Treatment Co.'s Patent
- Pa. Judge Greenlights State's 1st Opioid Marketing Case
- Joerns Gets Nod For $320M Debt-Equity Swap Ch. 11 Plan
- Ill. Marijuana Dispensary Wants Out Of Deal To Sell License
- CMA Accuses Pharmas Of Divvying Market For UTI Treatment
- Memory Booster Maker Can't Forget FTC False Ad Suit
- 5 Hard Phrases Lawyers Should Master
- MilliporeSigma's CRISPR Claims Put Pressure On USPTO
- J&J Digs Into Methods Of Expert Who Found Asbestos In Talc
- Bio-Rad Gets 10X's DNA Products Blocked, Plus $24M Cash
- Document Decision On Hold In J&J Talc Supplier's Ch. 11
- J&J Wasn't Alone In Talc Self-Regulation Push, Jury Hears
- ITC Bans Medical Device Imports That Flout Co.'s Trade Dress
- 3 Young Vapers Sue Juul Over Teen-Targeting Tactics
- Cities, Counties Lose Bid For Committee In Insys Ch. 11 Case
- Celgene To Pay $55M Over Cancer Drug Monopoly Claims
- How Roundup Trials Are Turning Jurors Into Activists
- Allergan Recalls Cancer-Linked Textured Breast Implants
- Impax May Be Trying To 'Game System' In Teva Fight: Judge
- Pfizer Can Pursue Claim For Securities MDL Coverage
- Insights From Recent Cases Considering Waiver Of Privilege
- Heritage Pharma, Former Execs Reach Deal In RICO Suit
- And Now A Word From The Panel: 4 MDL Lessons At 40
- Fed. Circ. Highlights Need For Enabling Disclosure In Patents
- J&J Grills Marketing Expert Who Said It Hid Mesh Risks
- Pelvic Mesh Victim Fights Bid To Seal Malpractice Filings
- Insys GC To Leave Embattled Co. After Less Than A Year
- 3rd Circ. Says Board Observers Not Same As Directors
- J&J Told FDA In '70s Asbestos In Talc Was Safe, Jury Hears
- Big Pharma Pounces On Bipartisan Drug Pricing Bill
- FDA Must Reconsider Denial Of Braeburn Anti-Opioid Drug
- Insys Pulls Support For Novel Gov't Entities Committee
- EpiPen Buyers Target Mylan CEO After Teva Disclosures
- Fed. Circ. Asked To Revive Parts Of Internal-Bleed Device IP
- Investors Clamor To Lead Suit Over Chemical Co. Stock Drop
- Mass. Biotech Co. Liable For CEO Duping Investors, SEC Says
- Nerve Repair Co. Says Stock-Drop Suit Relies On Iffy Sources
- $50M IRS Claim Holds Up Avadel Pharma Ch. 11 Confirmation
- Corcept Wants Sun's Cushing's Syndrome Drug Blocked
- Amgen, Allergan Launch 2 Biosimilars With Court's Blessing
- Calif. Expert Says J&J's 'Propaganda' Misled Mesh Patients
- DOJ Errors Doom Suboxone Film Fraud Case, Indivior Says
- Unlawful Pain Pill Sales Undeniable, Opioid MDL Counties Say
- Test Tube Cancer Research Beats Animal Studies, J&J Hears
- J&J Rep Battles Over Asbestos Definition At NJ Talc Trial
- Omnicell Stock Drop Followed Short Seller's Report, Suit Says
- FTC Asks 3rd Circ. To Revive Claims In AbbVie Antitrust Case
- Purdue Wants Fed. Circ. To Rehear OxyContin Patent Claims
- Strong Debut Augurs Well For China's New Startup Market
- Conn. Denies Leaking Heritage Doc In Generic-Drug Case
- Indian Hospitals Added To Indigenous Opioid Abuse, Feds Say
- Fed. Circ. Denies Stay In High Court-Bound Immunity Case
- Actavis Infringed Constipation Drug Patent, Judge Rules
- Feds Must Hand Over Info In Eye Product Kickback Suit
- Trustee, MDL Group, Maryland AG Blast Insys Ch. 11 Proposal
- ABA Rips USPTO Attorney Fee Rule As 'Radical'
- Books And Records Requests In The Era Of Text Messages
- Covington, Fried Frank Assist On $585M Deal For Dr. Scholl's
- E-Discovery Experts Could Increase Fed. Court Efficiency
- Software Biz Leads 3 Firms In IPO Launches Totaling $546M
- Fed. Circ. Leaves Open Questions On Patent Eligibility
- J&J Still Can't Transfer 2,400 Talc Suits To Del. Fed. Court
- DOJ Tries To Push CVS-Aetna Deal Past Court Review
- Endo Pharma To Pay $2.3M To 18 States In Lidoderm Deal
- Research Refutes J&J Talc Asbestos Claims, Jury Hears
- 'Everybody In The Crosshairs' As DOJ Opioid Blitz Gets Real
- 'Conspiracy' Claim Can't Save Antitrust Case, 7th Circ. Told
- Massachusetts Cases To Watch: Midyear Report
- Goodwin Guides Radiology Biz To $4B Valuation
- 4 Things FTC Competition Bureau Looks For In White Papers
- GSK Calls For Preemption Ruling In Zofran Birth Defect MDL
- Q&A With Skadden Mass Torts Leader John Beisner
- Ex-Merck Workers Get Green Light For $6.2M Sex Bias Deal
- Former Congressman Peter Roskam Joins Sidley Austin
- Preinstitution Submissions May Limit Certain ITC Probes
- Stryker Slams Zimmer's High Court Bid Following $254M Loss
- Talc Left 'Fingerprint' In Ky. Travel Agent's Lungs, Jury Hears
- Pfizer Wants Breast Cancer Drug MDL Consolidated In Del.
- Clark Hill Client Says Firm Pushed $1M Deal For His $63M Suit
- CVS Says It's 'Impossible' To Tell Who's In Price-Gouging Suit
- Pfizer Hid Risks Of Sepsis, Amputation On Labels, Suit Says
- Tax Court Hewed Too Closely To CUT In Medtronic, Atty Says
- Ill. Latest Battleground For Bayer In Essure Safety Suits
- Remembering Justice Stevens As A Law Firm Leader
- 5 Cos. Price IPOs Totaling $1.1B, Led By Danish Biotech Firm
- Texas Firms Aim To Dodge NJ Pelvic Mesh Malpractice Suit
- DOJ Indicts Opioid Distributor, Execs Over Painkiller Sales
- Drugmakers Tell 7th Circ. Insurer's Testosterone Suit Flawed
- A New Era For Human Genetic Resource Compliance In China
- Calif. Privacy Law's 3 Limited Exemptions For Health Cos.
- Martin Shkreli's Conviction Upheld By 2nd Circ.
- Ethicon Mesh Had Abysmal Success Rate, Surgeon Says
- 'May I Just Ask': Era Of Civility Passes With Justice Stevens
- Justice Stevens' Chevron Legacy Under Attack
- Sterigenics Settles Ill. Emissions Suit, Hopes To Reopen Plant
- 'Kindness, Humility, Wisdom': Justices Remember Stevens
- 6th Circ. Tosses Parents' Suit Over Merck's Gardasil
- The Stories They Tell About Justice Stevens
- Hear Justice Stevens In 5 Memorable Moments On The Bench
- 5 Times Justice Stevens Impacted Product Liability Law
- Justice Stevens' High Court Legacy In 4 Charts
- Express Scripts Can't Shake Pa. Records Fee Class Action
- FDA Must Hand Over Theranos Docs To Ex-CEO Holmes
- 4 Key Moments From J&J's Okla. Opioid Trial
- Tiversa Slams LabMD Exec's 'Late' Jury Trial Bid In FCA Suit
- Ariad Exec's Ex Asks 1st Circ. To Nix Insider Trade Conviction
- J&J Talc Supplier Chafes At Insurers' Ch. 11 Doc Demand
- Judge Invaded Jury's Role In Axing J&J Mesh Win, Court Told
- Deals Rumor Mill: Takeda, Dynata, Ferretti
- Loestrin Buyers Win Cert. In Antitrust Battle With Pharmas
- Surgeon Tells Calif. Judge Women's Bodies Reject J&J Mesh
- A Look Back At Justice Stevens' Most Important Opinions
- Justice John Paul Stevens' Brand Of Judicial Humility
- Retired Justice John Paul Stevens, Hero To Left, Dead At 99
- Insurer's Opioid Suit Not Rooted In Federal Law, Judge Says
- FCC Asked To Rescind TCPA Waiver In $925M Robocall Suit
- Records Show J&J Baby Powder Had Asbestos, NJ Jury Told
- Pa. Appeals Court Revives Risperdal Breast Growth Case
- Loestrin Buyers Seek Approval Of $1M Lupin Deal
- What High Court's Kisor Ruling Means For FDA Decisions
- Judge OKs Release Of National Opioid Sales Data
- Answers To Key Legal Finance Ethics Questions
- Preemption Vs. Public Nuisance, In Aviation And Opioids
- Pharmacy Benefit Cos. Improved Opioid Policies, Judge Says
- Former Insys Execs Want Sentencing Delayed Until 2020
- J&J Can't Quit Deception Playbook, Okla. Says In Closings
- Reckitt Hit With Stock Drop Suit Over $1.4B Opioid Probe Deal
- J&J Hid Painful Mesh Problems, Calif. Says At Trial's Start
- Fed. Circ. Backs Nobel Biocare Win In Dental Patent Case
- Impax's Discovery Delay Bid 'Beyond Unreasonable': Judge
- Investor Probing 'Activist' Fund's Role In Pet Firms' Tie-Up
- 4 Mesothelioma Patients Tell NJ Jury J&J Gave Them Cancer
- Philip Morris Looks To Stub Out Suit Over E-Cig Sales, Studies
- J&J Slams 'Gross Mischaracterization' Of Talc Ruling
- Arent Fox Brings FDA Pro Back From McCarter & English
- Pharma Foes Both Want Wins In Drug Access Antitrust Suit
- Federal Agencies Need A Uniform Record-Keeping Process
- E-Prescription Co. Hopes To Zap FTC Monopoly Case
- Insys Proposes Novel Gov't Committee Deal In Ch. 11 Case
- Investors Say Sales Potential Of Hair Transplant Robot Inflated
- Breaking Down J&J And California's $1B Pelvic Mesh Trial
- Avon Nears Costs Win After Cancer Victim Rejects $10K Deal
- J&J Again Asks For Win As Okla. Opioid Trial Testimony Ends
- How A Doc's FCA Suit Turned Into $1.4B Opioid Deal
- Fed. Circ. Largely Backs Generics In Suboxone Patent Fight
- Fla. Jury Absolves Zimmer In Hip Implant Injury Suit
- SEC Accuses 'Experienced' Securities Atty Of Trading Scheme
- Native American Cases To Watch In 2nd Half Of 2019
- No Summer Break Yet As 10 Firms Ready 9 IPOs For Market
- FDA Ordered To Impose 10-Month Deadline For E-Cig Apps
- Deals Rumor Mill: NSF, Clariant, Armacell
- Weak Ties To Imerys Ch. 11 Get J&J Talc Suit Remanded
- Merck Says Zetia Buyers Can't Expand Pay-For-Delay Suit
- L'Oreal Dodges Claims Over Misleading Cosmetics Bottles
- J&J Surgical Staplers Injured Man's Stomach, Suit Claims
- The Role Of Dictionaries In Last Term's High Court Decisions
- How To Evaluate The Rise In Legal Employment
- Tips For Patenting And Protecting Wearable Technology
- Allergan's Bid To Block Imprimis Drug Sales Limited To Calif.
- J&J Opioids Were Sliver Of The Okla. Market, Judge Told
- Fed. Circ. Unsure If PTAB Has To Explain Axing Avastin Patent
- Reed Smith Atty's Widow Fails To Reclaim $3M Win Over GSK
- Insurers Want To Investigate J&J Talc Supplier's Ch. 11
- Loestrin Buyers Fight To Advance Antitrust Case To Trial
- Prosthetic Maker Can't Save Acquisition, FTC Staffers Say
- Couple Sues Fertility Center For Implanting Wrong Embryos
- Deals Rumor Mill: J.Crew, AB InBev, Hitachi
- Abiomed Exec Should Get Paid Despite Firing, 1st Circ. Told
- IPO Surge Produces Record Exits For Venture Capital
- Eli Lilly Searches For New GC As Top Atty Plans To Retire
- Gilead Seeks To Nix Patients' Suit Over HIV Drug Toxicity
- Indiana AG Says Medical Debt Collector Belongs In Ch. 7
- Foreign Investment In US Biotech Gets Greater Gov't Scrutiny
- Cleary Guides Agilent's $1.17B Deal For BioTek Instruments
- Biosimilar Patent Litigation Bill Would Change BPCIA Strategy
- Reckitt To Pay $1.4B To End US Opioid Probe
- Opioid Crisis Not Ex-J&J Subsidiary's Fault, Exec Testifies
- Fed. Circ. Agrees Prenatal DNA Test Patent Doesn't Hold Up
- Fed. Circ. Pleads For Patent Eligibility Clarity: What Now?
- Ex-Illumina Accountant Traded Tips For NYC Trip, SEC Says
- New Trial Upheld For J&J After $417M Talc Verdict
- Trump Sizing Up India As New Trade Nemesis
- The Top Deals Of The First Half And The Firms That Led Them
- EU Clears GSK-Pfizer Joint Venture With Conditions
- Rival Can't Challenge Verdict Over Contract, Drug Co. Says
- Heritage Says Conn. Leaked Email About Congressional Probe
- Disciplinary Action Omission Prompts Atty Admission Redo
- Insys May Face Restitution Above $30M Penalty For Kickbacks
- GSK Gets 2nd Chance To Argue Preemption In Zofran MDL
- Investors' $1.95M Deal Over Merger Disclosures Gets OK
- 3 Takeaways From Nixing Of Drug Pricing Rule
- Cozen O'Connor DQ'd Over Client Conflict In Cannabis Deal
- Kirkland, Jones Day Guide $170M PE Deal For Aspen Surgical
- 3M Says Patient Attys' Sanctions Bid Over Docs Retaliatory
- Bio-Rad's $24M DNA Patent Win Backed By Evidence: Judge
- Okla. Says J&J Addiction Expert Is Just A 'Book Reviewer'
- Fla. Medical Marijuana Statute Deemed Unconstitutional
- BioScrip Investor Wants Option Care Merger Vote Halted
- The Business Case For Championing Diverse Legal Teams
- Deals Rumor Mill: Generali, WPP, Bayer
- Freshfields Guides Biotech Co. In $325M Funding Round
- Can Data Solve BigLaw's Diversity Problems?
- 12 Attorneys On How Diversity Gives Them The Edge
- Pa. Justices Urged To OK Experts In Pesticide Cancer Case
- Ex-CCO Says She Was Fired For Blowing Whistle On Boss
- Streaming Co. Leads 4 IPO Launches Set To Raise Over $1.8B
- Nursing Home Operator Owes $2M To Brain Clinic: 7th Circ.
- GSK Says Reed Smith Widow Can't Ignore 'Final Judgment'
- 3rd Circ. Suggests Remicade Fight May Require Arbitration
- What A Maturing Patent Bar Means For The Industry
- J&J Loses Bid To Escape Okla.'s Opioid Megatrial
- Sanofi, Eisai Back Lilly's $20M Cialis Patent Loss Challenge
- How The Legal Pipeline Is Failing Black Attorneys
- Judge Nixes Rule Forcing Drug Prices In TV Ads
- In Their Own Words: 9 Partners On Diversity At Work
- Ex-Atty, Informant Gets 1½ Years In $3.9M Trading Scheme
- The Best Firms For Minority Equity Partners
- Ex-Insys Bosses Still Aiding 8 Kickback Probes, Feds Say
- 3 Health Care-Focused Cos. Launch IPOs Totaling $277M
- The Art Of The 'Science And Expert Team' In Mass Torts
- Biggest Merger Reviews Of 2019: Midyear Report
- Akorn Investors Seek Cert. In Suit Over Failed Merger
- Cannabis-Related Patent, TM Filings Increase After Farm Bill
- Roche, Spark Extend Deadline For $4.8B Takeover Offer
- Misconceptions In The Debate About Noncompetes
- Diversity Efforts At Many Firms Ignore Disabled Attorneys
- Law360's Diversity Snapshot By The Numbers
- The Best Firms For Minority Attorneys
- Despite Progress, Firms Still Slow To Track LGBT Data
- J&J Cash Can't Sway Medicine's High Priests, Surgeon Says
- Product Liability Cases To Watch: Midyear Review
- Fractured Full Fed. Circ. Won't Eye Patent Eligibility Rules
- Okla. Opioid Case 'Should End Here And Now,' J&J Says
- J&J's Kirkland Attys Are Rehashing Old Fights, Judge Told
- Novum Pharma Seeks $3M Ch. 11 Loan To Fund Restructuring
- Latin American Energy Co., Biotech Firm Join IPO Pipeline
- AbbVie's $16.7M Inversion Settlement Gets Initial Approval
- Health Hires: Carlson & Jayakumar, Baker Donelson, Ropes
- 9th Circ. Seeks Nevada's Help With Defense Recoup Riddle
- The Top Antitrust Conduct Cases Of 2019: Midyear Report
- J&J Opioid Sales Rep Wooed 'Pill Mill' Doctors, Judge Hears
- 'Extraordinary' $100M Fraud Gets Ex-Pharma CEO 30 Years
- Supreme Court IP Recap: Patents
- Wilson Sonsini Blasts Zetia Buyers' Bid For More Docs
- Feds, Drugmakers Grilled Over Rule Mandating Prices In Ads
- 2 Firms Grab Spotlight In Scorching June For IPOs
- Cooley Hid Conflict While Helping Launch Company, Suit Says
- Insys Reaches Ch. 11 Deal To Pause State Opioid Suits
- NYC Doc Convicted In $2M Opioid Scheme Gets 5 Years
- 2 Firms Seek Lead In Investor Suits Over GTx-Oncternal Deal
- Antares Pharma Escapes Fraud Suit Over Drug Statements
- Sidley Helps Varian Ink $90M Deal To Bolster Cancer Portfolio
- Rethinking The Tech-First Approach To Law Firm Solutions
- Limits Of DOJ's Qui Tam Dismissal Authority Are Unsettled
- ITC To Investigate Intuitive Surgical's Cartridge Imports
- At Sentencing, Ex-CEO Argues $100M Fraud Didn't Sink Bank
- J&J's Addiction Expert Slammed For Touting Screening Tools
- Drug Return Co. Must Pay $94M Restitution In Fraud Case
- Sanofi Casting Blame For Failed EpiPen Rival, Mylan Says
- Pharmacy, PE Fund Near Deal To End Feds' FCA Kickback Suit
- Opioid MDL Litigants Seek Triumphs Before Bellwether Trial
- Finnegan Leveraged Vagisil's Fame To Block Rival's TM
- Valeant Investor Can't Duck Insider Trading Claims
- Biopharm Co. Gets Rare Jump On $17.4M Ch. 11 Asset Sales
- Haynes And Boone Snags 2 IP Partners From Brinks Gilson
- TWi Must Pay Fees After Ignoring Court Warnings In IP Row
- J&J Investors Fight To Keep Asbestos Stock-Drop Suit Alive
- How Opioid 'Negotiating Class' Would Affect Civil Claims
- BPI Supplement Doesn't Build Muscle As Promised, Suit Says